Kickback Suit Against Novartis Can Proceed, Judge Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal judge rules against Novartis’ motion to dismiss a whistleblower suit alleging violations of the anti-kickback statute and the False Claims Act, saying the government’s evidence is specific enough to proceed.
You may also be interested in...
AstraZeneca Settles Nexium Kickback Suit; Deals Prohibiting Authorized Generic Sales Alleged
AstraZeneca agreed to pay $7.9 million to resolve allegations it paid kickbacks to Medco Health Solutions for preferred formulary placement of Nexium.
Novo Probe By U.S. Expands To Insulin Manufacturing
Massachusetts U.S. Attorney’s office, which is also investigating firm’s marketing, now subpoenas Novo Nordisk for documents relating to potential issues at its plant in Kalundborg, Denmark.
Health Care Fraud Tipsters May Get Bigger Reward; Novartis Kickback Complaint Prompts CIA Review
HHS proposes to increase the potential reward for information leading to recovery of Medicare funds from $1,000 to $9.9 million; OIG is reviewing Novartis corporate integrity agreement compliance after government alleges company paid Myfortic kickbacks to pharmacies.